Who are Mosaic ImmunoEngineering, Inc.'s main suppliers?

Mosaic ImmunoEngineering, Inc. (CPMV) key suppliers include: INVESTOR, CWRU. View the full supplier network at chainsifter.com/chain/CPMV.

Who are Mosaic ImmunoEngineering, Inc.'s major customers?

Mosaic ImmunoEngineering, Inc. (CPMV) key customers include: ONCOTELIC, AstraZeneca PLC, AstraZeneca PLC, Bristol-Myers Squibb Company, Bristol-Myers Squibb Company and 10 more. View the full customer network at chainsifter.com/chain/CPMV.

What sector is Mosaic ImmunoEngineering, Inc. in?

Mosaic ImmunoEngineering, Inc. (CPMV) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Mosaic ImmunoEngineering, Inc. Supply Chain Data (CPMV): 19 Verified Relationships

2Suppliers

15Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Mosaic ImmunoEngineering, Inc. (CPMV) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

19Total relationships

2Distinct source URLs

5High confidence

0.755Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Mosaic ImmunoEngineering, Inc. Suppliers

Ticker	Name	Confidence	Evidence
INVESTOR	INVESTOR	90%	On November 18, 2024, we entered into an unsecured convertible promissory note ("Note Purchase Agreement") with an accredited investor ("Investor") for proceeds of up to $200,000 to be used for gener…
CWRU	CWRU	85%	On May 4, 2022 we exercised our rights under the License Option Agreement and entered into a license agreement with CWRU ("License Agreement"). Pursuant to the terms of the License Agreement, we agre…

Mosaic ImmunoEngineering, Inc. Customers

Ticker	Name	Confidence	Evidence
ONCOTELIC	ONCOTELIC	92%	On July 1, 2024, we entered into a Master Services Agreement with Oncotelic whereby we perform advisory and related services in connection with studies and projects. During the years ended December 3…
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from AZN grap…
AZN	AstraZeneca PLC	72%	ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia…
BMY	Bristol-Myers Squibb Company	72%	ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia…
BMY	Bristol-Myers Squibb Company	72%	Reciprocal relationship from BMY graph: Reciprocal relationship from CPMV graph: ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or …
BMYMP	Bristol-Myers Squibb Co	72%	ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia…
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from CPMV graph: ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents o…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from MRK grap…
MRK	Merck & Co., Inc.	72%	ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CPMV graph: ate our business without infringi…
NVSEF	Novartis AG	72%	ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia…
OTLC	Oncotelic Therapeutics, Inc.	72%	ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercia…
OTLC	Oncotelic Therapeutics, Inc.	72%	Reciprocal relationship from OTLC graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from OTLC graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from OTLC g…
ISSUER-DIRECT-CORPORATION	ISSUER-DIRECT-CORPORATION	62%	ovision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opport…
SECURITIES-INVESTOR-PROTECTION-CORPORATION	SECURITIES-INVESTOR-PROTECTION-CORPORATION	62%	ts have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and include the accounts of Mosaic ImmunoEngineering, Inc. and our subsidiaries. All inte…

Mosaic ImmunoEngineering, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CPMV-DEBT-8818	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.
CPMV-DEBT	Debt stack $1.7M	90%	Market cache reports total debt of $1.7M.

Mosaic ImmunoEngineering, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Mosaic ImmunoEngineering, Inc..

Mosaic ImmunoEngineering, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Mosaic ImmunoEngineering, Inc..

Mosaic ImmunoEngineering, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ALLO	Allogene Therapeutics, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
IMMP	Immutep Limited	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
DEO	Diageo plc	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	1	['customer']
BCAX	Bicara Therapeutics Inc.	100.00	2

Mosaic ImmunoEngineering, Inc. Supply Chain